Legal Update: Johnson & Johnson Talc Litigation and Recent Jury Verdicts
The legal landscape surrounding Johnson & Johnson’s talc-based products remains complex and evolving. As of mid-2026, the company continues to navigate a significant volume of litigation brought by plaintiffs who allege that its talc products are contaminated with asbestos and linked to serious health outcomes, including ovarian cancer and mesothelioma.
Recent Developments in Talc Litigation
A Los Angeles jury recently ruled in favor of Johnson & Johnson, finding that the company was not negligent in the marketing of its talc-based cosmetic products. The case was brought by the families of three women who had passed away from ovarian cancer. During the proceedings, jurors evaluated evidence regarding the safety of talc, with the company maintaining that its products are safe, do not contain asbestos, and do not cause cancer.
This verdict follows a similar defense win in an Oklahoma court, reflecting the mixed outcomes Johnson & Johnson has encountered as cases proceed through the court system. These trials have resumed following the company’s unsuccessful attempts to resolve the litigation through bankruptcy proceedings. Notably, a bankruptcy judge rejected an $8 billion settlement proposal in March 2025, which was intended to resolve ovarian cancer claims.
Understanding the Claims
The core of the ongoing litigation involves tens of thousands of claimants. While Johnson & Johnson has reached settlements in the majority of cases alleging that its talc products caused mesothelioma—a rare form of cancer associated with asbestos exposure—the vast majority of remaining active lawsuits focus on allegations of ovarian cancer.
Erik Haas, the company’s vice-president of litigation, has characterized the claims regarding ovarian cancer as being rooted in what the company describes as “junk science.” Conversely, plaintiffs argue that the company knew its products could contain asbestos—a known carcinogen—and failed to provide adequate warnings to the public.
Shift in Product Strategy
Amidst the mounting legal challenges and evolving consumer safety concerns, Johnson & Johnson took significant steps to change its product portfolio. In 2020, the company ceased the sale of talc-based baby powder in the United States and Canada, transitioning instead to a cornstarch-based formula for its baby powder products.
Key Takeaways
- Ongoing Litigation: Over 67,000 plaintiffs have filed lawsuits alleging that Johnson & Johnson’s talc products caused ovarian cancer.
- Legal Hurdles: A proposed $8 billion settlement was rejected by a bankruptcy judge in early 2025, forcing cases back into the court system.
- Varied Verdicts: The company has experienced a range of outcomes in court, securing recent defense verdicts in Los Angeles and Oklahoma, while facing significant judgments in other instances.
- Product Transition: Johnson & Johnson discontinued the sale of talc-based baby powder in the U.S. Market in 2020, replacing it with a cornstarch-based alternative.
As these cases move forward, the legal system continues to weigh conflicting evidence regarding the safety and composition of talc products. The outcome of these trials remains a focal point for both the company and the families seeking compensation for health-related grievances.
Disclaimer: This article is for informational purposes only and does not constitute legal or medical advice. If you have concerns about your health or potential legal claims, please consult with a qualified professional.
Related reading
- Is Your Crown Thinning? How to Tell If It’s Hair Loss
- Pennsylvania Measles Outbreak: Fourth Death Reported Amid Rising Cases
- Akron Fires Officer Who Killed 15-Year-Old, Settles Lawsuit for $4.75 Million (news-usa.today)
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)